PAR1 PHARMACOECONOMIC ANALISIS OF THE TREATMENT WITH LEFLUNOMIDEMETHOTREXATE OR INFLIXIMABMETHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS RESISTANT TO METHOTREXATE  by Rubio Terrés, C et al.
475Abstracts
groups, costs were analyzed using a propensity score
model. Conﬁdence intervals were estimated using boot-
strap methods. RESULTS: Population in the two groups
was balanced for age, gender, weight and body mass
index. The groups differed signiﬁcantly in terms of
housing status (p < 0.05) and nutritional status (p <
0.001). Adjusted costs per patient of hospital care 
(-€551), nursing care (-€145) and other medical care
were signiﬁcantly reduced in the FNS group as compared
to the LNS group, with cost savings of -€723 (90% CI:
-€1.444 to -€43). Including oral supplementation costs,
the total cost savings per patient attributable to nutrition
support were -€195 (90% CI: -€929 to +€478). CON-
CLUSION: Appropriate nutrition diagnosis and support
may contribute to reduce the costs of health care. Propen-
sity score models are a valuable framework for the analy-
sis of cost data, when it is not possible to conduct
randomized studies.
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OBJECTIVE: To compare the efﬁciency of leﬂunomide-
methotrexate or inﬂiximab-methotrexate in patients 
with rheumatoid arthritis resistant to methotrexate.
METHODS: Cost-minimization pharmacoeconomic
model that compared treatments administered at the 
recommended doses and regimens during a 12-month
period. Use of resources and unit costs were estimated
from Spanish sources. Simple univariate sensitivity analy-
sis was made of the base case. RESULTS: In two 
randomized, placebo-controlled clinical trials available,
the ACR20 and ACR50 responses rates at 6 months 
were 46.2% and 25.4%, respectively, with leﬂunomide-
methotrexate and 50.0% and 27.0%, respectively, with
inﬂiximab-methotrexate (2P = 0.57 and 2P = 0.82). The
estimated cost per patient of annual treatment with
leﬂunomide-methotrexate or inﬂiximab-methotrexate is
€2,823 versus €11,489, respectively (incremental cost of
€8,666). Sensitivity analysis conﬁrmed the robustness 
of the base case, with incremental costs of inﬂiximab-
methotrexate ranging from €7,500 to €9,500. In order to
equalize the costs per patient of these alternatives, the cost
of acquisition of a package of Inﬂiximab would have to
decrease from the present €637.59 to a hypothetical 
cost of €33.10. CONCLUSIONS: The cost per patient 
of twelve months of treatment with the combination of
inﬂiximab-methotrexate is greater than that of leﬂuno-
mide-methotrexate, due mainly to the higher acquisition
cost of Inﬂiximab.
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OBJECTIVES: To examine the sick rate of rheumatoid
arthritis in Ukraine in 1996 to 2001. Celecoxib is a new
COX-2-inhibitor drug. Randomized controlled clinical
trials—RCCTs showed, that celecoxib is safer than 
non-steroidal anti-ﬂammatory drugs (NSAIDs). To
analyse direct medical costs for treatment celecoxib vs
NSAIDs with gastroprotective agents in patients with
rheumatoid arthritis from the perspective of public health
care in Ukraine. METHODS: A decision tree model in
Ukraine based on the use of clinical data from literature.
Eight RCCTs showed a signifﬁcantly higher incidence of
ulcer—the 6-month rates of ulcer were 5,89% for
NSAIDs vs 1,64% for celecoxib, and for NSAID plus
proton-pump ingibitor (PPI)—1,94%. Only direct costs
associated with three alternatives: celecoxib; NSAID 
only; NSAID plus PPI (six months) were analysed. All
prices are expressed in Ukranian hryvnas (UAH). The
incremental cost-effectiveness ratio was determined.
RESULTS: The sick rate of rheumatoid arthritis from
1996 to 2001 was increased 8,6% per year in Ukraine.
The direct costs of celebrex and NSAID only were com-
parable 905,4 UAH vs 897,5 (1USD = 5,2 UAH), but the
NSAID plus PPI was signiﬁcantly more costly 1216,1
UAH per one patient. The incremental cost-effectiveness
ratio for celecoxib was 1,86 UAH; NSAID plus PPI—80,6
UAH per 1% of ulcer reduction. The total cost of 100
patients treated with celecoxib was 90540 UAH than
NSAIDs plus PPI was 95822 UAH. The threshold analy-
sis suggests that celecoxib would be the dominant therapy
if its cost was to decrease by 58%. CONCLUSIONS: The
treatment with Celecoxib is more effective and safe than
NSAID only, and to be cost-effective than NSAID plus
PPI in Ukraine.
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